Phibro Animal Health Corporation (PAHC) recently completed the acquisition of Zoetis Inc.’s (ZTS) medicated feed additive (MFA) product portfolio and certain water-soluble products. The latest acquisition comes with a lineup of products across cattle, swine and poultry, which will complement and expand Phibro’s species and product portfolios. This will help the company’s customers meet the highest standards of animal care, prevent diseases and enhance nutrition around the world. PAHC’s Likely Stock Trend Fo ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style S ...

Wall Street is sitting on its hands on Monday and Tuesday waiting for Alphabet, Microsoft, Apple, Amazon, and other mega-cap technology stocks to report their results in the final week of October.See the Zacks Earnings Calendar to stay ahead of market-making news. Amid the recent choppiness, some stocks are ripping to 52-week highs. Today we explore a screen that helps investors find soaring stocks trading near fresh highs that are also experiencing impressive upward earnings revisions activity, helping the ...

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision tren ...

文章核心观点 - 公司拥有多元化的产品组合和广泛的全球业务布局,有利于抓住全球增长机遇 [1][2] - 公司专注于新疫苗技术的开发和产能扩张,为公司带来增长动力 [3] - 公司的主要产品包括饲料添加剂和营养特殊产品,有助于提升动物营养,同时公司也在积极发展宠物业务 [4] - 尽管公司股价在过去一年内涨幅低于行业平均水平,但凭借创新和并购等战略举措,预计未来股价将继续上涨 [5] 公司业务概况 - 公司在全球80多个国家拥有销售、营销和分销网络,在高增长地区如巴西、中国、印度等布局广泛 [2] - 公司专注于新疫苗技术的开发和产能扩张,如在巴西新建了一家疫苗生产设施 [3] - 公司的主要产品包括饲料添加剂和营养特殊产品,如Stafac/V-Max/Eskalin、OmniGen-AF和Animate等,广泛应用于家禽、猪和奶牛等行业 [4] - 公司也在积极发展宠物业务和管线 [4] 行业发展趋势 - 公司所处行业整体呈现较好的增长态势,公司有望从中受益 [1][2] - 但矿物营养和性能产品业务受到宏观环境的不利影响,销售和利润增长面临一定压力 [6]

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive ...

It has been about a month since the last earnings report for Phibro Animal Health (PAHC) . Shares have added about 2.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Phibro due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Phibro Q4 Earnings and Revenues Beat, Oper ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Abbott (ABT) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our ...

Phibro Animal Health Corporation's (PAHC) sustained growth in the Animal Health business is backed by robust sales of vaccines and Medicated Feed Additives ("MFAs"). The company's focus on advancing vaccine technologies, along with the new vaccine production unit, instills optimism. Strong sales growth outside the United States seems encouraging. Yet, adverse macroeconomic impacts are a concern for Phibro's operations. In the past year, this Zacks Rank #2 (Buy) stock has rallied 71.5% compared with the indu ...

Phibro Animal Health's (PAHC) diversified product portfolio and wide presence in key growth areas bolster our confidence in the stock. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving PAHC's Growth Phibro's key animal health products, including Medicated Feed Additives (MFAs) and nutritional specialty products, enhance animal nutrition. The company's leading product franchise, Stafac/V-Max/Eskalin, is approved in more than 30 countries for use in poultry and swine. Similarly, the company's ...